Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer

被引：48

作者：

de Marinisa, Filippo ^{[1
]}

Grossi, Francesco ^{[2
]}

机构：

[1] San Camillo & Forlanini Hosp, Thorac Oncol Unit 1, Dept Lung Dis, Rome, Italy

[2] Natl Inst Canc Res, Dis Management Team Lung Canc, Genoa, Italy

来源：

ONCOLOGIST | 2008年 / 13卷

关键词：

NSCLC; second-line chemotherapy; pemetrexed; docetaxel; erlotinib;

D O I：

10.1634/theoncologist.13-S1-14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small Cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.

引用

页码：14 / 20

页数：7

共 35 条

[1] Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials [J].

Bria, Emilio ;

Cuppone, Federica ;

Ciccarese, Mariangela ;

Nistio, Cecilia ;

Facciolo, Francesco ;

Milella, Michele ;

Izzo, Fiorentino ;

Terzoli, Edmondo ;

Cognetti, Francesco ;

Giannarelli, Diana .

CANCER TREATMENT REVIEWS, 2006, 32 (08) :583-587

[2] Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer:: a Spanish Lung Cancer Group trial [J].

Camps, C ;

Massuti, B ;

Jiménez, A ;

Maestu, I ;

Gómez, RG ;

Isla, D ;

González, JL ;

Almenar, D ;

Blasco, A ;

Rosell, R ;

Carrato, A ;

Viñolas, N ;

Batista, N ;

Girón, CG ;

Galán, A ;

López, M ;

Blanco, R ;

Provencio, M ;

Diz, P ;

Felip, E .

ANNALS OF ONCOLOGY, 2006, 17 (03) :467-472

[3] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[4] Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial [J].

Dancey, J ;

Shepherd, FA ;

Gralla, RJ ;

Kim, YS .

LUNG CANCER, 2004, 43 (02) :183-194

[5] Second-line treatment options in non-small cell lung cancer: A comparison of cytotoxic agents and targeted therapies [J].

de Marinis, F ;

De Santis, S ;

De Petris, L .

SEMINARS IN ONCOLOGY, 2006, 33 (01) :S17-S24

[6] Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non small-cell lung cancer [J].

Di Maio, Massimo ;

Perrone, Francesco ;

Chiodini, Paolo ;

Gallo, Ciro ;

Camps, Carlos ;

Schuette, Wolfgang ;

Quoix, Elisabeth ;

Tsai, Chun-Ming ;

Gridelli, Cesare .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1377-1382

[7] ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC) [J].

Felip, E ;

Stahel, RA ;

Pavlidis, N .

ANNALS OF ONCOLOGY, 2005, 16 :28-29

[8] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[9] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[10] Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) [J].

Gervais, R ;

Ducolone, A ;

Breton, JL ;

Braun, D ;

Lebeau, B ;

Vaylet, F ;

Debieuvre, D ;

Pujol, JL ;

Tredaniel, J ;

Clouet, P ;

Quoix, E .

ANNALS OF ONCOLOGY, 2005, 16 (01) :90-96

← 1 2 3 4 →